About Us
Finding new & better treatments for Type 1 Diabetes
The Type 1 Diabetes UK Immunotherapy Consortium (T1D UK) was set up in 2015 with major funding from Diabetes UK & the JDRF, to promote, develop and support immunotherapy research in T1D.
T1D UK has established a network of 24 Research Sites strategically distributed across the UK to recruit children and adults into clinical trials of new immunotherapy treatments in T1D
There are 2 main cores to T1D UK, a clinical engagement & training core (CET) led by Prof Colin Dayan from Cardiff University and a mechanistic core of 5 specialist Labs located throughout the UK, led by Tim Tree from Kings College, London.
Colin Dayan explains immunotherapy for T1D – here interviewed by Vivienne Parry OBE prior to a plenary lecture at the EASD in Berlin Sept 2018.